A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.

[1]  Tsuyoshi Saito,et al.  GNAS mutation as an alternative mechanism of activation of the Wnt/β-catenin signaling pathway in gastric adenocarcinoma of the fundic gland type. , 2014, Human pathology.

[2]  E. Cornwell,et al.  Appendiceal Mucinous Neoplasm , 2014 .

[3]  R. Reis,et al.  Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs) , 2014, European Journal of Human Genetics.

[4]  J. Davison,et al.  GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival. , 2014, Human pathology.

[5]  C. Amos,et al.  Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. , 2014, Clinical chemistry.

[6]  K. Frazer,et al.  Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin , 2014, Genome Medicine.

[7]  J. Davison,et al.  Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade , 2014, Modern Pathology.

[8]  R. Celestino,et al.  TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas , 2014, The Journal of clinical endocrinology and metabolism.

[9]  Yasunori Sato,et al.  GNAS and KRAS Mutations are Common in Intraductal Papillary Neoplasms of the Bile Duct , 2013, PloS one.

[10]  David T. W. Jones,et al.  Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system , 2013, Acta Neuropathologica.

[11]  D. Schadendorf,et al.  TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism , 2013, Proceedings of the National Academy of Sciences.

[12]  A. Rashid,et al.  High-level Microsatellite Instability in Appendiceal Carcinomas , 2013, The American journal of surgical pathology.

[13]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[14]  Poonam K Sharma,et al.  Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis. , 2013, The Journal of surgical research.

[15]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[16]  T. Mori,et al.  Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms , 2013, British Journal of Cancer.

[17]  Thierry Soussi,et al.  The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis , 2012, Nucleic Acids Res..

[18]  H. Tsuda,et al.  Frequent activating GNAS mutations in villous adenoma of the colorectum , 2012, The Journal of pathology.

[19]  P. Chu,et al.  Determining the Site of Origin of Mucinous Adenocarcinoma: An Immunohistochemical Study of 175 Cases , 2011, The American journal of surgical pathology.

[20]  Masakazu Yamamoto,et al.  Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas , 2011, Scientific reports.

[21]  T. Bishop,et al.  Ki-ras gene mutations are invariably present in low-grade mucinous tumors of the vermiform appendix , 2011, Scandinavian journal of gastroenterology.

[22]  J. Misdraji.  Appendiceal mucinous neoplasms: controversial issues. , 2010, Archives of pathology & laboratory medicine.

[23]  H. Lee,et al.  Differential protein immunoexpression profiles in appendiceal mucinous neoplasms: a special reference to classification and predictive factors , 2009, Modern Pathology.

[24]  A. Flanagan,et al.  GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma , 2009, Modern Pathology.

[25]  R. Yantiss,et al.  A Comprehensive Study of Nondysplastic and Dysplastic Serrated Polyps of the Vermiform Appendix , 2007, The American journal of surgical pathology.

[26]  A. Flanagan,et al.  A sensitive mutation‐specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone , 2007, Histopathology.

[27]  R. Wada,et al.  Immunohistochemical expressions of cytokeratins, mucin core proteins, p53, and neuroendocrine cell markers in epithelial neoplasm of appendix. , 2005, Human pathology.

[28]  B. Vojtesek,et al.  Discriminating functional and non‐functional p53 in human tumours by p53 and MDM2 immunohistochemistry , 2005, The Journal of pathology.

[29]  R. Yantiss,et al.  Appendiceal Mucinous Neoplasms: A Clinicopathologic Analysis of 107 Cases , 2003, The American journal of surgical pathology.

[30]  A. Terano,et al.  Molecular and genetic characterization of a non-metastatic human esophageal cancer cell line, T.Tn expressing non-functional mutated p53. , 2002, International journal of oncology.

[31]  L. Sobin,et al.  Epithelial neoplasms of the appendix and colorectum: an analysis of cell proliferation, apoptosis, and expression of p53, CD44, bcl-2. , 2002, Archives of pathology & laboratory medicine.

[32]  Wareef Kabbani,et al.  Mucinous and Nonmucinous Appendiceal Adenocarcinomas: Different Clinicopathological Features but Similar Genetic Alterations , 2002, Modern Pathology.

[33]  K. Jablonski,et al.  Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. , 1995, Human pathology.

[34]  F. Lanza,et al.  The abnormal p53 proteins expressed in CML cell lines are non-functional. , 1993, Leukemia.

[35]  E. Clementi,et al.  A new constitutively activating mutation of the Gs protein alpha subunit-gsp oncogene is found in human pituitary tumours. , 1990, Oncogene.

[36]  B. Moran,et al.  Pseudomyxoma peritonei usually originates from the appendix: a review of the evidence. , 2004, European journal of gynaecological oncology.